IOL Chemicals Outlines INR 500 Crore Capex Across Strategic Growth Initiatives
IOL Chemicals & Pharmaceuticals Ltd · Transcript · 17 Sept 2026, 10:33 pm
IOL Chemicals Outlines INR 500 Crore Capex Across Strategic Growth Initiatives IOL Chemicals is investing ~INR 500 crore via internal accruals across three initiatives to drive an incremental 25–30% top-line growth by FY29 and achieve >15% company-wide ROCE. Capex includes expanding fully backward-integrated Ibuprofen capacity by 6,000 MTPA to 18,000 MTPA (commissioning Dec'27), entering CDMO formulations with a 1,500 million tablets/annum EU-GMP certified facility (commercializing Q3 FY27), and setting up a dedicated specialty chemical tolling facility. Around 30% of funds are already deployed, with full utilization of new facilities targeted over 18–24 months post-commissioning.
Original exchange filing (PDF)
More announcements from IOL Chemicals & Pharmaceuticals Ltd
- Clarification on increase in Volume · 11 Nov 2026
- The Exchange has sought clarification from IOL Chemicals & Pharmaceuticals Ltd on November 11, 2026, with reference to Movement in Volume. <BR><BR>The reply is awaited. · 11 Nov 2026
- Transcript of Earning Call on the Q2 & H1 FY27 Financial Results · 05 Nov 2026
- Audio Recording of Earnings Call on the Q2 & H1 FY 27 Financial Results · 02 Nov 2026
- Investor Presentation- Q2 & H1 FY27 · 02 Nov 2026
- Press Release · 31 Oct 2026
- Outcome of the Board Meeting and submission of Unaudited Financial Results of the Company for the quarter and half year ended 30th September 2026 · 30 Oct 2026
- Submission of Financial Results · 30 Oct 2026
